Perbak Capital Partners LLP Axsome Therapeutics, Inc. Transaction History
Perbak Capital Partners LLP
- $568 Billion
- Q3 2025
A detailed history of Perbak Capital Partners LLP transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Perbak Capital Partners LLP holds 6,313 shares of AXSM stock, worth $881,862. This represents 0.13% of its overall portfolio holdings.
Number of Shares
6,313
Previous 4,728
33.52%
Holding current value
$881,862
Previous $494 Million
55.34%
% of portfolio
0.13%
Previous 0.11%
Shares
2 transactions
Others Institutions Holding AXSM
# of Institutions
414Shares Held
36.8MCall Options Held
752KPut Options Held
567K-
Vanguard Group Inc Valley Forge, PA4.18MShares$584 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.3MShares$461 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA1.33MShares$186 Million0.03% of portfolio
-
Rtw Investments, LP New York, NY1.12MShares$156 Million1.82% of portfolio
-
Macquarie Group LTD Australia, C31.08MShares$151 Million0.16% of portfolio
About Axsome Therapeutics, Inc.
- Ticker AXSM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,878,000
- Market Cap $5.99B
- Description
- Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...